Abstract YO16
Case summary
Thai male patient, 58 years old
He had been diagnosed essential hypertension and dyslipidemia for over 10 years (2005) and received cadaveric donor kidney transplantation on Oct 2005.
In May 2017, he presented with left hip closed fracture, in plain film of Lt hip had showed osteolytic lesion at left head and neck of femur with fracture at intertrochanter of femur.
He received bone biopsy and result showed metastatic clear cell renal cell carcinoma.
On CT chest and whole abdomen include pelvis had seen heterogeneous enhancing mass at right native kidney size 7.1 x 7.2 x 8.5 cm with synchronous lesion at transplanted kidney size 1.1 x 1.4 cm and pathological lymph nodes at internal iliac artery, no distance metastasis.
He underwent surgery to debulk tumor and hemiarthroplasty of left hip and received post-operative radiotherapy. Post-operative, he had been added everolimus 0.5 mg per day.
He starts treatment with Pazopanib since June 2007 until now and has hand foot syndrome grade I, diarrhea grade I, his blood pressure is well controlled and now he still has partial response.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract